Allergic Rhinitis (AR) Clinical Trial
Official title:
A Randomized Controlled Trial of Tian Jiu Therapy for Allergic Rhinitis
Verified date | March 2017 |
Source | Hong Kong Baptist University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this study is to investigate the efficacy and safety of Tian Jiu in the treatment of allergic rhinitis compared with placebo and waitlist patients in Hong Kong.
Status | Completed |
Enrollment | 136 |
Est. completion date | September 2016 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 3 Years and older |
Eligibility |
Inclusion Criteria: - Positive skin prick tests - High circulating levels of allergen-specific IgE antibody detected by a specific blood test for allergy called radioallergosorbent test (RAST)] - Clinical history or allergen to have been identified - Nasal provocation (test) Exclusion Criteria: - Allergic asthma, moderate to severe atopic dermatitis, autoimmune disorders, severe chronic inflammatory diseases, history of anaphylactic reactions, hypersensitivity to cetirizine or related drugs, specific immunotherapy during the past 3 years or planned in the next 2 years, pregnancy or breastfeeding. |
Country | Name | City | State |
---|---|---|---|
China | Hong Kong Baptist University Chinese Medicine Clinic | Hong Kong |
Lead Sponsor | Collaborator |
---|---|
Hong Kong Baptist University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change of total nasal symptom score | The change in the weekly average of total nasal symptom score (TNSS) recorded in participants' diaries from baseline( Week 0) to end of the treatment( Week 4)and post-treatment follow-up ( Week 8) | 4 weeks | |
Secondary | Change of the Rhinitis Quality of Life Questionnaire (RQLQ) | The change in symptoms will be measured using the Rhinitis Quality of Life Questionnaire (RQLQ), by comparing the baseline( Week 0) with the scores within treatment (Week 2, 3), end of treatment( Week 4) and post-treatment follow-up ( Week 8). | 8 weeks | |
Secondary | Change in need for medication | The change in need for medication will be measured using an RM score (RMS), by comparing the baseline (Week 0) with the scores within treatment (Week 2, 3), end of treatment( Week 4) and post-treatment follow-up ( Week 8). | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01371786 -
A Phase 1 Scintigraphy Study to Assess Nasal Deposition of Ciclesonide. Using a Novel Nasal Metered Dose Inhaler
|
Phase 1 |